Used in the pharmaceutical industry as a potent and selective inhibitor of Janus kinase 1 (JAK1), this compound is investigated for its therapeutic potential in treating autoimmune and inflammatory diseases. It shows promise in conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease by modulating cytokine signaling pathways involved in immune response. Due to its targeted mechanism, it may offer improved safety and reduced side effects compared to broad-spectrum immunosuppressants. The compound is also explored in oncology research for its role in disrupting signaling pathways that contribute to certain hematologic malignancies. Its development supports the design of orally available small-molecule therapies with high bioavailability and CNS penetration.